GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » EBITDA Margin %

Kuros Biosciences (XSWX:KURN) EBITDA Margin % : -38.57% (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kuros Biosciences's EBITDA for the six months ended in Dec. 2023 was CHF-7.98 Mil. Kuros Biosciences's Revenue for the six months ended in Dec. 2023 was CHF20.70 Mil. Therefore, Kuros Biosciences's EBITDA margin for the quarter that ended in Dec. 2023 was -38.57%.


Kuros Biosciences EBITDA Margin % Historical Data

The historical data trend for Kuros Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences EBITDA Margin % Chart

Kuros Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -330.26 -212.35 -38.30 -72.35 -31.01

Kuros Biosciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -121.23 2.47 -175.53 -18.86 -38.57

Competitive Comparison of Kuros Biosciences's EBITDA Margin %

For the Medical Devices subindustry, Kuros Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's EBITDA Margin % falls into.



Kuros Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kuros Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-10.409/33.564
=-31.01 %

Kuros Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-7.983/20.698
=-38.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuros Biosciences  (XSWX:KURN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Kuros Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences (XSWX:KURN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines